Research programme: haemophilia therapeutics - Baxter/GenOdyssee
Latest Information Update: 01 Apr 2011
At a glance
- Originator Baxter International; GenOdyssee
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Haemophilia
Most Recent Events
- 26 Oct 2006 Preclinical trials in Haemophilia in France (unspecified route)